Sankar B R, Maran R R, Sivakumar R, Govindarajulu P, Balasubramanian K
Department of Endocrinology, Dr. ALM. PG. Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai, India.
J Steroid Biochem Mol Biol. 2000 Mar;72(3-4):155-62. doi: 10.1016/s0960-0760(00)00019-4.
The mechanism involved in the inhibitory actions of chronic corticosterone treatment on Leydig cell steroidogenesis was studied in adult Wistar rats. Rats were treated with corticosterone-21-acetate (2 mg/100 g body weight, i.m., twice daily) for 15 days and another set of rats was treated with corticosterone plus ovine luteinizing hormone (oLH) (100 microg/kg body weight, s.c., daily) for 15 days. Chronic treatment with corticosterone increased serum corticosterone but decreased serum LH, testosterone, estradiol and testicular interstitial fluid (TIF) testosterone and estradiol concentrations. Administration of LH with corticosterone partially prevented the decrease in serum and TIF testosterone and estradiol. Leydig cell LH receptor number, basal and LH-stimulated cAMP production were diminished by corticosterone treatment which remained at control level in the corticosterone plus LH treated rats. Activities of steroidogenic enzymes, 3beta- and 17beta-hydroxysteroid dehydrogenase (3beta-HSD and 17beta-HSD) were significantly decreased in corticosterone treated rats. LH plus corticosterone treatment did not affect 3beta-HSD activity but decreased 17beta-HSD activity, indicating a direct inhibitory effect of excess corticosterone on Leydig cell testosterone synthesis. The indirect effect of corticosterone, thus, assume to be mediated through lower LH which regulates the activity of 3beta-HSD. Basal, LH and cAMP-stimulated testosterone production by Leydig cells of corticosterone and corticosterone plus LH treated rats were decreased compared to control suggesting the deleterious effect of excess corticosterone on LH signal transduction and thus steroidogenesis.
在成年Wistar大鼠中研究了慢性皮质酮治疗对睾丸间质细胞类固醇生成的抑制作用机制。大鼠用醋酸皮质酮-21(2mg/100g体重,肌肉注射,每日两次)治疗15天,另一组大鼠用皮质酮加羊促黄体生成素(oLH)(100μg/kg体重,皮下注射,每日)治疗15天。慢性皮质酮治疗可增加血清皮质酮,但降低血清促黄体生成素、睾酮、雌二醇以及睾丸间质液(TIF)中的睾酮和雌二醇浓度。皮质酮与促黄体生成素联合给药可部分防止血清和TIF中睾酮和雌二醇的降低。皮质酮治疗可降低睾丸间质细胞促黄体生成素受体数量、基础和促黄体生成素刺激的环磷酸腺苷(cAMP)生成,而在皮质酮加促黄体生成素治疗的大鼠中,这些指标维持在对照水平。皮质酮治疗的大鼠中,类固醇生成酶3β-和17β-羟基类固醇脱氢酶(3β-HSD和17β-HSD)的活性显著降低。促黄体生成素加皮质酮治疗不影响3β-HSD活性,但降低17β-HSD活性,表明过量皮质酮对睾丸间质细胞睾酮合成有直接抑制作用。因此,皮质酮的间接作用被认为是通过降低调节3β-HSD活性的促黄体生成素介导的。与对照组相比,皮质酮和皮质酮加促黄体生成素治疗的大鼠睾丸间质细胞基础、促黄体生成素和cAMP刺激的睾酮生成均降低,提示过量皮质酮对促黄体生成素信号转导及类固醇生成具有有害作用。